Mark S. Sapienza, MD

I see patients at the following locations:

Education

Bachelor’s Degree – Franklin & Marshall College

Medical Degree – Loyola University – Stritch School of Medicine

Internship – Thomas Jefferson University Hospital

Residency – Thomas Jefferson University Hospital

Fellowship – Thomas Jefferson University Hospital

Board Certifications – Internal Medicine, Gastroenterology

Honors & Awards

  • Top Doctors 2024, Bergen Magazine
  • Clinical Teaching Award 2003, Englewood Hospital
  • Top Doctors 2008, 2013, 2016-2020 NJ Magazine
  • Top Doctors 2012-2016, 201 Magazine
  • Doctor of the Year 2015, Englewood Hospital
  • New York Magazine: Top Doctors: 2016, 2018, 2020
  • Castle Connolly Regional Top Doctors: 1st Edition
  • Jersey’s Best Magazine Top Doctors: 2016, 2017, 2018, 2019
  • Top Doctors New York Metro Area (digital guide): 2016, 2017, 2018, 2019, 2020, 2021

Specialties & Main Areas of Interest

  • Liver Disease
  • Inflammatory Bowel Disease

Hospital Affiliations

  • Englewood Hospital
  • Holy Name Hospital
  • Hackensack Meridian School of Medicine – Assistant Professor in the Department of Medicine (non-clinical affiliation)

Other Appointments

  • Chief, Section of Gastroenterology, 2016-current
  • Associate Chief, Section of Gastroenterology, 2010-2016
  • Chair, EHMC Credentials Committee, 2013
  • P&T Committee at Englewood Hospital P&T Committee, 2003-current
  • President of NJ Gastroenterology & Endoscopy Society (NJGES), 2006-2007
  • President of NJ Gastrointestinal PAC (GIPAC), 2007-2014
  • Secretary/Treasurer, EHMC Medical Staff, 2014-2016
  • Vice President, EHMC Medical Staff, 2016-2018
  • President, EHMC Medical Staff, 2018-2020
  • EHMC Hospital Board Member (ex officio), 2016-current

Research

  • Yellowstone Study – Principal Investigator. Multi center clinical research trial to determine if the investigational medication ozanimod is safe and effective for the treatment of moderately to severe active Crohn’s disease
  • PN 943-03 Study – Principal Investigator. A phase II randomized double blind placebo-controlled multi-center study to evaluate the safety and efficacy of oral PN-943 in subjects with moderate to severe active ulcerative coliti
When Should You Get Screened?

According to the American Cancer Society, for average-risk individuals, screening for colorectal cancer is generally recommended to begin at age 45. However, if you have a family history of colorectal cancer, inflammatory bowel disease (IBD), or other risk factors, your doctor may recommend starting before age 45.

 
Schedule Your Screening Today

We encourage you to discuss your screening options with your physician. They can help you determine the most appropriate screening method based on your individual risk factors and preferences.

Schedule Your Colonoscopy

Choose a Location